Growth Ventures

A bold approach to Venture Capital with a growth mindset.

Thesis

Bold Genesis Growth Ventures pairs a founder-first growth playbook with an investor-grade risk-return engine. 

We back profitable-or-near-profitably companies that have cracked product-market fit, then accelerate them with minority capital, revenue-share returns, and fractional C-suite muscle. 

Founders keep the steering wheel; investors see cash-flow-driven liquidity plus equity-style upside—hedged by our focus on high-growth, B2B verticals and disciplined governance.

Founders

Schedule your Screening

Unlock an operator-level review of your growth engine. In a brief call we’ll map your revenue trajectory, identify the bottlenecks we can clear, and confirm whether our minority-capital + fractional-talent model is the right fit. Leave with actionable insights—even if we don’t invest.

Investors

Request our Pitch Deck

See how our “growth-without-surrender” strategy delivers cash-flow liquidity and equity-style upside while hedging downside through sector focus and tailored covenants. Get the deck, review our thesis, and explore co-invest or LP opportunities for Fund I.

About

Bold Genesis Growth Ventures™

The roots of “Bold Genesis” trace back to an innovative personal health–tech concept that later re-emerged as NuVeeta. Continual curiosity and disciplined execution then carried the brand into private-equity circles, where it refined a evidence-based and data-driven practice in Human Capital Risk Management. Each chapter sharpened our insight into how people, process, and capital converge to create durable value.

Today, those lessons fuel our evolution into a venture-capital firm that blends start-up agility with PE-grade rigor. We seek founders who turn complex problems into scalable opportunities, and we stand beside them with operational know-how, deep networks, and disciplined governance.

Our approach is boldly simple: deploy capital with a growth-equity mindset, hedge exposure through targeted investments, and transform calculated risk into compound returns.